% | $
Quotes you view appear here for quick access.

Prima Biomed Ltd. Message Board

  • drivrb drivrb Oct 18, 2012 11:47 PM Flag

    CVac ovarian cancer treatment could be a winner for the company

    Interim progression free survival data show a favourable trend toward patients receiving CVac staying in remission longer than those in the observational standard of care (OSC) group. Combining overall data of first and second remission, the median progression free survival time (as of the date of data cut-off) is 421 days for non-randomized CVac, 365 days for CVac, and 321 days for OSC. The first seven patients on the study were not randomized and all seven were assigned to receive CVac in accordance with the trial design.

0.875+0.005(+0.57%)Oct 25 3:59 PMEDT